Minesse (Ethinylestradiol, Gestodene | Lactose Monohydrate)

Ethinylestradiol (an estrogen) and Gestodene (a progestogen) act together to suppress the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), thereby inhibiting ovulation. The progestogen also thickens cervical mucus and alters the endometrial lining, creating additional barriers to fertilisation and implantation.

The specific dosing regimen for Minesse is determined by the prescribing healthcare professional. Typically, the medication is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions must be provided by the prescriber.

Minesse is contraindicated during pregnancy and should not be started in women who are already pregnant. While limited data exist for breastfeeding, most guidelines advise caution; the benefits and risks should be evaluated by a healthcare professional before use in lactating women.

To order Minesse, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Minesse contains Ethinylestradiol and Gestodene, a low‑dose estrogen‑progestogen combination that offers a favorable balance of efficacy and tolerability. Compared with older formulations that use higher estrogen doses, Minesse may present a lower risk of estrogen‑related side effects while maintaining comparable contraceptive effectiveness.

Minesse tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Minesse is taken orally, usually as one tablet each day. The tablet should be swallowed whole with water, preferably at the same time each day to maintain consistent hormone levels. If a dose is missed, follow the prescriber’s instructions or the product’s patient information leaflet.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Women should seek immediate medical attention if they experience sudden leg pain, shortness of breath, chest pain, severe headache, or visual changes, as these may signal a life‑threatening complication.

Minesse is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or who are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.